GeneDx Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

GeneDx Holdings wird ein Gewinn- und Umsatzwachstum von 57.1% bzw. 13.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 63.5% pro Jahr wachsen soll.

Wichtige Informationen

57.1%

Wachstumsrate der Gewinne

63.5%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	13.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Feb 23

Recent updates

GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

Jun 12

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

Jun 06

Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

Apr 24

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Feb 23

The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Feb 22

Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Dec 20

Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Nov 02

Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Nov 01

Sema4 names Kevin Feeley as CFO

Aug 26

Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Aug 20

Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 19

Sema4 Q2 2022 Earnings Preview

Aug 12

Sema4 Holdings, Big Data For Precision Medicine Solutions

Jul 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:WGS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	327	N/A	N/A	N/A	2
12/31/2025	276	-47	N/A	N/A	4
12/31/2024	242	-77	N/A	N/A	4
3/31/2024	222	-135	-147	-141	N/A
12/31/2023	203	-176	-186	-180	N/A
9/30/2023	206	-459	-221	-215	N/A
6/30/2023	236	-494	-272	-262	N/A
3/31/2023	224	-533	-304	-293	N/A
12/31/2022	235	-549	-333	-319	N/A
9/30/2022	231	-280	-326	-306	N/A
6/30/2022	191	-170	-308	-289	N/A
3/31/2022	202	-131	-249	-230	N/A
12/31/2021	212	-245	-211	-190	N/A
9/30/2021	218	-331	-181	-157	N/A
6/30/2021	214	-420	-140	-114	N/A
3/31/2021	197	-406	-144	-113	N/A
12/31/2020	179	-241	-125	-93	N/A
12/31/2019	196	-33	-34	-19	N/A
12/31/2018	133	-27	-29	-25	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: WGS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: WGS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: WGS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: WGSDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: WGSDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von WGS in 3 Jahren voraussichtlich hoch sein wird

GeneDx Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 41%

GeneDx Holdings Corp. Updates Earnings Guidance for the Year 2024

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2024

Price target increased by 8.6% to US$7.88

Genedx Holdings Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Recent updates

President exercised options and sold US$218k worth of stock

GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

Consensus estimates of losses per share improve by 41%

President exercised options and sold US$70k worth of stock

GeneDx Holdings Corp., Annual General Meeting, Jun 20, 2024

GeneDx Holdings Corp. Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

Genedx Announces Partnership with Komodo Health to Expand Access to World’S Largest Rare Disease Dataset

GeneDx Holdings Corp. to Report Q1, 2024 Results on Apr 29, 2024

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Full year 2023 earnings: EPS and revenues exceed analyst expectations

The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2024

Price target increased by 8.6% to US$7.88

GeneDx Holdings Corp. to Report Q4, 2023 Results on Feb 20, 2024

Genedx Holdings Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Executive Chair of the Board recently bought US$161k worth of stock

Consensus EPS estimates fall by 20%

Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GeneDx Holdings Corp. Updates Revenue Guidance for the Full Year 2023

GeneDx Holdings Corp. to Report Q3, 2023 Results on Oct 30, 2023

Genedx Holdings Corp. Announces Executive Appointments

Price target decreased by 8.4% to US$10.88

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GeneDx Holdings Corp. Reiterates Earnings Guidance for the Year 2023 and 2025

GeneDx Holdings Corp. to Report Q2, 2023 Results on Aug 08, 2023

GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

President recently sold US$56k worth of stock

Consensus EPS estimates upgraded to US$6.74 loss

Price target increased by 10% to US$52.25

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GeneDx Holdings Corp. Reiterates Earnings Guidance for the Year 2023

GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option

Full year 2022 earnings: EPS and revenues miss analyst expectations

GeneDx Holdings Corp. Announces Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

GeneDx Holdings Corp. Announces Resignation of Michael Pellini from the Board of Directors

Sema4 Holdings Corp. Provides Revenue Guidance for the Year 2023

Sema4 Announced the Results of A New Study on Mitochondrial Diseases in Newborns

CEO & Director recently bought US$100k worth of stock

Consensus forecasts updated

High number of new directors

Sema4 Holdings Corp. Reaffirms Its Earnings Guidance for the Full Year and Second Half 2022

Sema4 Holdings Corp. to Report Q3, 2022 Results on Nov 14, 2022

Sema4 Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

The Gross Law Firm Notifies Shareholders of Sema4 Holdings, Corp. of Class Action Lawsuit and Lead Plaintiff Deadline of November 7, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Sema4 Holdings Corp

Sema4 Holdings Corp. Announces Chief Financial Officer Changes

Sema4 names Kevin Feeley as CFO

Consensus revenue estimates fall by 21%

Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Sema4 Holdings Corp. Revises Revenue Guidance for the Fiscal 2022

Sema4 Announces Executive Changes

Price target decreased to US$3.75

Sema4 Holdings Corp. Provides Earnings Guidance for the Second Half and Full Year 2022

Sema4 Q2 2022 Earnings Preview

Sema4 Holdings Corp. to Report Q2, 2022 Results on Aug 15, 2022

Sema4 Holdings, Big Data For Precision Medicine Solutions

Sema4 Holdings Corp. Announces Executive Changes

Sema4 Announces Executive Changes, Effective August 9, 2022

Founder recently bought US$192k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Sema4 Holdings Corp. Reaffirms Previously Issued Full Year 2022 Guidance

Founder recently sold US$78k worth of stock